In this pharmacogenetic study in adults with ADHD (n= 42), a stratified analysis was
performed of the association between response to methylphenidate (MPH), assessed under …

Gene polymorphisms of the 3′ untranslated region (3′‐UTR) of the dopamine transporter
(DAT1), Dopamine receptor exon 3 D4 variable number tandem repeat (DRD4VNTR) …

Attention-deficit/hyperactivity disorder (ADHD) is a prevalent childhood-onset
neuropsychiatric disorder. Treatment with methylphenidate, which blocks dopamine and …

Attention deficit-hyperactivity disorder (ADHD) is a very common and heterogeneous
childhood-onset psychiatric disorder, affecting between 3% and 5% of school age children …

Pharmacogenetic studies investigating the 40‐bp VNTR polymorphism at SLC6A3 and
methylphenidate response have shown conflicting results and large differences in study …

Results from pharmacogenetic investigations of methylphenidate (MPH) response in
patients with ADHD are still inconsistent, especially among adults. This study investigates …

A polymorphism in the dopamine transporter gene (DAT1) has been previously associated
with ADHD and methylphenidate has been hypothesized to block the dopamine transporter …

We sought to test the hypothesis that the variable number of tandem repeat (VNTR)
polymorphism in the 3′-untranslated region (3′-UTR) of the SLC6A3 gene modulates …

The dopamine transporter locus (DAT1) has been studied as a risk factor for attention-
deficit/hyperactivity disorder (ADHD) and in pharmacogenetic studies of stimulant response …

Stimulant medications, such as methylphenidate (MPH), are the most commonly used,
effective treatment for ADHD. MPH acts primarily by inhibiting the dopamine transporter …